Patent intelligence · US
US 12419955
Method for efficiently infecting human natural killer cells and other immune cells with pseudovirus
Method for efficiently infecting human natural killer cells and other immune cells with pseudovirus
Patent details — US 12419955
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 23, 2025
- Expiration
- Sep 18, 2045
- Applicant
- Beijing Gene MINK Biotechnology CO.LTD
- Claims
- 7
- CPC classes
- A61K, A61K2239/11, A61K40/11, A61K40/15
Quick answer
US 12419955 (Method for efficiently infecting human natural killer cells and other immune cells with pseudovirus) is held by Beijing Gene MINK Biotechnology CO.LTD. Status: granted. Granted Sep 23, 2025. Expires Sep 18, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Beijing Gene MINK Biotechnology CO.LTD
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K2239/11, A61K40/11, A61K40/15, A61K40/31, A61K40/4202
More from Beijing Gene MINK Biotechnology CO.LTD
Related pharmaceutical patents in our USPTO index.
-
US 12391741
T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
granted -
US 11898165
Engineered host cells and methods of use thereof
granted -
US 11718658
T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
granted -
US 11613764
T cell receptors that bind to NY-ESO-1 and methods of use thereof
granted -
US 9943496
Dietary supplement based on ethyl ferulate
granted
Frequently asked questions
What is US patent 12419955?
US 12419955 (Method for efficiently infecting human natural killer cells and other immune cells with pseudovirus) is held by Beijing Gene MINK Biotechnology CO.LTD. Status: granted. Granted Sep 23, 2025. Expires Sep 18, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12419955?
Beijing Gene MINK Biotechnology CO.LTD is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 12419955 expire?
Our index shows an expiration date of Sep 18, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.